-

01:29:05 AM

ASLN Stock News

ASLN - ASLAN Pharmaceuticals Ltd

05/25/21 7:30 AM

Nasdaq : ASLN

conferences

ASLAN Pharmaceuticals to Participate In Fireside Chat at Jefferies Virtual Healthcare Conference

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will

RHEA-AI

neutral

05/11/21 7:30 AM

Nasdaq : ASLN

earnings

ASLAN Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

ASLAN Pharmaceuticals

RHEA-AI

neutral

05/05/21 5:22 AM

Nasdaq : ASLN

conferences

ASLAN Pharmaceuticals to Present Data on ASLAN004 at Society for Investigative Dermatology

ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage immunology focused biopharmaceutical company

RHEA-AI

neutral

04/22/21 7:51 AM

Nasdaq : ASLN

earnings

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company

RHEA-AI

negative

03/18/21 7:27 AM

Nasdaq : ASLN

management

ASLAN Pharmaceuticals Appoints Dr Kathleen Metters as Independent Director

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent

RHEA-AI

neutral

03/03/21 12:42 AM

Nasdaq : ASLN

offering

ASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the pricing of an underwritten public offering of 15,000,000

RHEA-AI

neutral

03/01/21 4:01 PM

Nasdaq : ASLN

offering

ASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has commenced an underwritten public offering of $60.0

RHEA-AI

neutral

03/01/21 6:00 AM

Nasdaq : ASLN

ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis

- 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90 - Data supportive of ASLAN004’s potential as a novel, first-in-class antibody targeting IL-13R with differentiated efficacy and safety profile in atopic

RHEA-AI

neutral

02/25/21 6:30 AM

Nasdaq : ASLN

ASLAN Pharmaceuticals Announces $18 Million Private Placement

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has entered into a securities purchase agreement to raise

RHEA-AI

neutral

02/18/21 7:00 AM

Nasdaq : ASLN

management

ASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent Director

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Neil Graham, MBBS, MD, MPH as an independent

RHEA-AI

neutral

Prev 1 2 3 4 5 Next

ASLN Data

IndustryPharmaceutical Preparation Manufacturing
Websiteaslanpharma.com
CeoCarl Firth
Security nameASLAN Pharmaceuticals Ltd - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees2020
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
State12 03 Ue Square
City83 Clemenceau Avenue
Zip239920
CountrySingapore
Phone6562224235

About ASLAN Pharmaceuticals Ltd

ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PSX). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs.